Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
1284 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alzheimer's Disease - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H2 2016', provides an overview of the Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease - The report reviews pipeline therapeutics for Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Alzheimer's Disease therapeutics and enlists all their major and minor projects - The report assesses Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Alzheimer's Disease Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 12 Alzheimer's Disease Overview 13 Therapeutics Development 14 Alzheimer's Disease - Therapeutics under Development by Companies 16 Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 37 Alzheimer's Disease - Pipeline Products Glance 44 Alzheimer's Disease - Products under Development by Companies 48 Alzheimer's Disease - Products under Investigation by Universities/Institutes 78 Alzheimer's Disease - Companies Involved in Therapeutics Development 88 Alzheimer's Disease - Therapeutics Assessment 316 Drug Profiles 372 Alzheimer's Disease - Dormant Projects 1152 Alzheimer's Disease - Discontinued Products 1199 Alzheimer's Disease - Product Development Milestones 1209 Appendix 1221
List of Tables
Number of Products under Development for Alzheimer's Disease, H2 2016 76 Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H2 2016 77 Number of Products under Development by Companies, H2 2016 79 Number of Products under Development by Companies, H2 2016 (Contd..1) 80 Number of Products under Development by Companies, H2 2016 (Contd..2) 81 Number of Products under Development by Companies, H2 2016 (Contd..3) 82 Number of Products under Development by Companies, H2 2016 (Contd..4) 83 Number of Products under Development by Companies, H2 2016 (Contd..5) 84 Number of Products under Development by Companies, H2 2016 (Contd..6) 85 Number of Products under Development by Companies, H2 2016 (Contd..7) 86 Number of Products under Development by Companies, H2 2016 (Contd..8) 87 Number of Products under Development by Companies, H2 2016 (Contd..9) 88 Number of Products under Development by Companies, H2 2016 (Contd..10) 89 Number of Products under Development by Companies, H2 2016 (Contd..11) 90 Number of Products under Development by Companies, H2 2016 (Contd..12) 91 Number of Products under Development by Companies, H2 2016 (Contd..13) 92 Number of Products under Development by Companies, H2 2016 (Contd..14) 93 Number of Products under Development by Companies, H2 2016 (Contd..15) 94 Number of Products under Development by Companies, H2 2016 (Contd..16) 95 Number of Products under Development by Companies, H2 2016 (Contd..17) 96 Number of Products under Development by Companies, H2 2016 (Contd..18) 97 Number of Products under Development by Companies, H2 2016 (Contd..19) 98 Number of Products under Investigation by Universities/Institutes, H2 2016 99 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 100 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 101 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 102 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 103 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 104 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 105 Comparative Analysis by Late Stage Development, H2 2016 106 Comparative Analysis by Clinical Stage Development, H2 2016 107 Comparative Analysis by Early Stage Development, H2 2016 108 Comparative Analysis by Unknown Stage Development, H2 2016 109 Products under Development by Companies, H2 2016 110 Products under Development by Companies, H2 2016 (Contd..1) 111 Products under Development by Companies, H2 2016 (Contd..2) 112 Products under Development by Companies, H2 2016 (Contd..3) 113 Products under Development by Companies, H2 2016 (Contd..4) 114 Products under Development by Companies, H2 2016 (Contd..5) 115 Products under Development by Companies, H2 2016 (Contd..6) 116 Products under Development by Companies, H2 2016 (Contd..7) 117 Products under Development by Companies, H2 2016 (Contd..8) 118 Products under Development by Companies, H2 2016 (Contd..9) 119 Products under Development by Companies, H2 2016 (Contd..10) 120 Products under Development by Companies, H2 2016 (Contd..11) 121 Products under Development by Companies, H2 2016 (Contd..12) 122 Products under Development by Companies, H2 2016 (Contd..13) 123 Products under Development by Companies, H2 2016 (Contd..14) 124 Products under Development by Companies, H2 2016 (Contd..15) 125 Products under Development by Companies, H2 2016 (Contd..16) 126 Products under Development by Companies, H2 2016 (Contd..17) 127 Products under Development by Companies, H2 2016 (Contd..18) 128 Products under Development by Companies, H2 2016 (Contd..19) 129 Products under Development by Companies, H2 2016 (Contd..20) 130 Products under Development by Companies, H2 2016 (Contd..21) 131 Products under Development by Companies, H2 2016 (Contd..22) 132 Products under Development by Companies, H2 2016 (Contd..23) 133 Products under Development by Companies, H2 2016 (Contd..24) 134 Products under Development by Companies, H2 2016 (Contd..25) 135 Products under Development by Companies, H2 2016 (Contd..26) 136 Products under Development by Companies, H2 2016 (Contd..27) 137 Products under Development by Companies, H2 2016 (Contd..28) 138 Products under Development by Companies, H2 2016 (Contd..29) 139 Products under Investigation by Universities/Institutes, H2 2016 140 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 141 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 142 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 143 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 144 Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 145 Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 146 Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 147 Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 148 Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 149 Alzheimer's Disease - Pipeline by AB Science SA, H2 2016 150 Alzheimer's Disease - Pipeline by AbbVie Inc, H2 2016 151 Alzheimer's Disease - Pipeline by AC Immune SA, H2 2016 152 Alzheimer's Disease - Pipeline by Accera, Inc., H2 2016 153 Alzheimer's Disease - Pipeline by Acelot, Inc., H2 2016 154 Alzheimer's Disease - Pipeline by Actinogen Limited, H2 2016 155 Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals, Inc., H2 2016 156 Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 157 Alzheimer's Disease - Pipeline by Affibody AB, H2 2016 158 Alzheimer's Disease - Pipeline by AFFiRiS AG, H2 2016 159 Alzheimer's Disease - Pipeline by Alector LLC, H2 2016 160 Alzheimer's Disease - Pipeline by Alkermes Plc, H2 2016 161 Alzheimer's Disease - Pipeline by Allergan Plc, H2 2016 162 Alzheimer's Disease - Pipeline by Allinky Biopharma, H2 2016 163 Alzheimer's Disease - Pipeline by ALSP, Inc., H2 2016 164 Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H2 2016 165 Alzheimer's Disease - Pipeline by Alzinova AB, H2 2016 166 Alzheimer's Disease - Pipeline by AlzProtect SAS, H2 2016 167 Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 168 Alzheimer's Disease - Pipeline by Amgen Inc., H2 2016 169 Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp., H2 2016 170 Alzheimer's Disease - Pipeline by Aphios Corporation, H2 2016 171 Alzheimer's Disease - Pipeline by Apodemus AB, H2 2016 172 Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences, S.L., H2 2016 173 Alzheimer's Disease - Pipeline by Araclon Biotech, S.L., H2 2016 174 Alzheimer's Disease - Pipeline by Archer Pharmaceuticals, Inc., H2 2016 175 Alzheimer's Disease - Pipeline by ArmaGen Inc., H2 2016 176 Alzheimer's Disease - Pipeline by Artery Therapeutics, Inc., H2 2016 177 Alzheimer's Disease - Pipeline by AskAt Inc., H2 2016 178 Alzheimer's Disease - Pipeline by Astellas Pharma Inc., H2 2016 179 Alzheimer's Disease - Pipeline by AstraZeneca Plc, H2 2016 180 Alzheimer's Disease - Pipeline by Asubio Pharma Co., Ltd., H2 2016 181 Alzheimer's Disease - Pipeline by Ausio Pharmaceuticals, LLC, H2 2016 182 Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016 183 Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H2 2016 184 Alzheimer's Disease - Pipeline by Axovant Sciences Ltd., H2 2016 185 Alzheimer's Disease - Pipeline by Axsome Therapeutics, Inc., H2 2016 186 Alzheimer's Disease - Pipeline by Axxam SpA, H2 2016 187 Alzheimer's Disease - Pipeline by Beactica AB, H2 2016 188 Alzheimer's Disease - Pipeline by Berg LLC, H2 2016 189 Alzheimer's Disease - Pipeline by BioArctic Neuroscience AB, H2 2016 190 Alzheimer's Disease - Pipeline by Bioasis Technologies Inc., H2 2016 191 Alzheimer's Disease - Pipeline by Biogen Inc, H2 2016 192 Alzheimer's Disease - Pipeline by Biomar Microbial Technologies, H2 2016 193 Alzheimer's Disease - Pipeline by Bionature E.A. Ltd., H2 2016 194 Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2016 195 Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H2 2016 196 Alzheimer's Disease - Pipeline by Bsim2, H2 2016 197 Alzheimer's Disease - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016 198 Alzheimer's Disease - Pipeline by Carna Biosciences, Inc., H2 2016 199 Alzheimer's Disease - Pipeline by Celon Pharma Sp. z o.o., H2 2016 200 Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2016 201 Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H2 2016 202 Alzheimer's Disease - Pipeline by Clera Inc., H2 2016 203 Alzheimer's Disease - Pipeline by Cognition Therapeutics, Inc., H2 2016 204 Alzheimer's Disease - Pipeline by Cognosci, Inc., H2 2016 205 Alzheimer's Disease - Pipeline by CohBar, Inc., H2 2016 206 Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 207 Alzheimer's Disease - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 208 Alzheimer's Disease - Pipeline by Corium International, Inc., H2 2016 209 Alzheimer's Disease - Pipeline by Coronis Partners Ltd., H2 2016 210 Alzheimer's Disease - Pipeline by Cortice Biosciences, Inc., H2 2016 211 Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc., H2 2016 212 Alzheimer's Disease - Pipeline by Crossbeta Biosciences B.V., H2 2016 213 Alzheimer's Disease - Pipeline by D-Pharm Ltd., H2 2016 214 Alzheimer's Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 215 Alzheimer's Disease - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 216 Alzheimer's Disease - Pipeline by Daval International Limited, H2 2016 217 Alzheimer's Disease - Pipeline by DermaXon, LLC, H2 2016 218 Alzheimer's Disease - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016 219 Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H2 2016 220 Alzheimer's Disease - Pipeline by Eli Lilly and Company, H2 2016 221 Alzheimer's Disease - Pipeline by Emergent BioSolutions Inc., H2 2016 222 Alzheimer's Disease - Pipeline by EncephRx, Inc., H2 2016 223 Alzheimer's Disease - Pipeline by Endece, LLC, H2 2016 224 Alzheimer's Disease - Pipeline by ENKAM Pharmaceuticals A/S, H2 2016 225 Alzheimer's Disease - Pipeline by Ensemble Therapeutics Corporation, H2 2016 226 Alzheimer's Disease - Pipeline by Ensol Biosciences Inc., H2 2016 227 Alzheimer's Disease - Pipeline by Epigen Biosciences, Inc., H2 2016 228 Alzheimer's Disease - Pipeline by Euroscreen S.A., H2 2016 229 Alzheimer's Disease - Pipeline by Evotec AG, H2 2016 230 Alzheimer's Disease - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 231 Alzheimer's Disease - Pipeline by FORUM Pharmaceuticals Inc., H2 2016 232 Alzheimer's Disease - Pipeline by Genentech, Inc., H2 2016 233 Alzheimer's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2016 234 Alzheimer's Disease - Pipeline by GlaxoSmithKline Plc, H2 2016 235 Alzheimer's Disease - Pipeline by GliaCure Inc., H2 2016 236 Alzheimer's Disease - Pipeline by Glialogix, Inc., H2 2016 237 Alzheimer's Disease - Pipeline by Golden Biotechnology Corp., H2 2016 238 Alzheimer's Disease - Pipeline by Grifols, S.A., H2 2016 239 Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2016 240 Alzheimer's Disease - Pipeline by Heptares Therapeutics Limited, H2 2016 241 Alzheimer's Disease - Pipeline by HitGen LTD, H2 2016 242 Alzheimer's Disease - Pipeline by Humanetics Corporation, H2 2016 243 Alzheimer's Disease - Pipeline by Ichor Medical Systems, Inc., H2 2016 244 Alzheimer's Disease - Pipeline by Icure Pharmaceutical Inc., H2 2016 245 Alzheimer's Disease - Pipeline by Immungenetics AG, H2 2016 246 Alzheimer's Disease - Pipeline by Impel NeuroPharma, Inc., H2 2016 247 Alzheimer's Disease - Pipeline by ImStar Therapeutics Inc., H2 2016 248 Alzheimer's Disease - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 249 Alzheimer's Disease - Pipeline by IntelGenx Corp., H2 2016 250
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
